journal
Journals Cytometry. Part B, Clinical Cy...

Cytometry. Part B, Clinical Cytometry

https://read.qxmd.com/read/38572669/possible-alternative-strategies-to-implement-basophil-activation-testing-in-multicentric-studies
#1
JOURNAL ARTICLE
Pénélope Bourgoin, Thomas Dupont, Chantal Agabriel, Ania Carsin, Aurélie Verles, Maciej Cabanski, Alessandra Vitaliti, Jean-Marc Busnel
The Basophil Activation Test (BAT) enables flow cytometry characterization of basophil reactivity against specific allergenic molecules. The focus now revolves around democratizing this tool, but, as blood sample stability could be challenging, after having developed a simplified approach, herein, we aimed to characterize two strategies for implementing BAT in multicentric studies: store and ship blood before or after sample processing. Fresh heparin- and EDTA-anticoagulated whole blood samples followed both BAT workflows: "collect, store, process & analyze" or "collect, process, store & analyze"...
April 4, 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38535092/performance-of-a-novel-eight-color-flow-cytometry-panel-for-measurable-residual-disease-assessment-of-chronic-lymphocytic-leukemia
#2
JOURNAL ARTICLE
Xiao Chen, Xia Chen, Sishu Zhao, Yu Shi, Ninghan Zhang, Zhen Guo, Chun Qiao, Huimin Jin, Liying Zhu, Huayuan Zhu, Jianyong Li, Yujie Wu
BACKGROUND: Measurable residual disease (MRD) is an important prognostic indicator of chronic lymphocytic leukemia (CLL). Different flow cytometric panels have been developed for the MRD assessment of CLL in Western countries; however, the application of these panels in China remains largely unexplored. METHODS: Owing to the requirements for high accuracy, reproducibility, and comparability of MRD assessment in China, we investigated the performance of a flow cytometric approach (CD45-ROR1 panel) to assess MRD in patients with CLL...
March 27, 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38418432/optimization-of-a-flow-cytometry-test-for-routine-monitoring-of-b-cell-maturation-antigen-targeted-car-in-peripheral-blood
#3
JOURNAL ARTICLE
Won-Ho Lee, Charlotte E Graham, Hadley R Wiggin, Hannah K Nolan, Kiana J Graham, Felix Korell, Mark B Leick, Alexis L Barselau, Estelle Emmanuel-Alejandro, Michael A Trailor, Juliane M Gildea, Frederic Preffer, Matthew J Frigault, Marcela V Maus, Kathleen M E Gallagher
Chimeric antigen receptor (CAR) modified T cell therapies targeting BCMA have displayed impressive activity in the treatment of multiple myeloma. There are currently two FDA licensed products, ciltacabtagene autoleucel and idecabtagene vicleucel, for treating relapsed and refractory disease. Although correlative analyses performed by product manufacturers have been reported in clinical trials, there are limited options for reliable BCMA CAR T detection assays for physicians and researchers looking to explore it as a biomarker for clinical outcome...
February 28, 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38415807/magic-dr-an-interpretable-machine-learning-guided-approach-for-acute-myeloid-leukemia-measurable-residual-disease-analysis
#4
JOURNAL ARTICLE
Kevin Shopsowitz, Jack Lofroth, Geoffrey Chan, Jubin Kim, Makhan Rana, Ryan Brinkman, Andrew Weng, Nadia Medvedev, Xuehai Wang
Multiparameter flow cytometry is widely used for acute myeloid leukemia minimal residual disease testing (AML MRD) but is time consuming and demands substantial expertise. Machine learning offers potential advancements in accuracy and efficiency, but has yet to be widely adopted for this application. To explore this, we trained single cell XGBoost classifiers from 98 diagnostic AML cell populations and 30 MRD negative samples. Performance was assessed by cross-validation. Predictions were integrated with UMAP as a heatmap parameter for an augmented/interactive AML MRD analysis framework, which was benchmarked against traditional MRD analysis for 25 test cases...
February 28, 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38407537/recommendations-for-using-artificial-intelligence-in-clinical-flow-cytometry
#5
JOURNAL ARTICLE
David P Ng, Paul D Simonson, Attila Tarnok, Fabienne Lucas, Wolfgang Kern, Nina Rolf, Goce Bogdanoski, Cherie Green, Ryan R Brinkman, Kamila Czechowska
Flow cytometry is a key clinical tool in the diagnosis of many hematologic malignancies and traditionally requires close inspection of digital data by hematopathologists with expert domain knowledge. Advances in artificial intelligence (AI) are transferable to flow cytometry and have the potential to improve efficiency and prioritization of cases, reduce errors, and highlight fundamental, previously unrecognized associations with underlying biological processes. As a multidisciplinary group of stakeholders, we review a range of critical considerations for appropriately applying AI to clinical flow cytometry, including use case identification, low and high risk use cases, validation, revalidation, computational considerations, and the present regulatory frameworks surrounding AI in clinical medicine...
February 26, 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38396223/translating-the-regulatory-landscape-of-medical-devices-to-create-fit-for-purpose-artificial-intelligence-ai-cytometry-solutions
#6
REVIEW
Goce Bogdanoski, Fabienne Lucas, Wolfgang Kern, Kamila Czechowska
The implementation of medical software and artificial intelligence (AI) algorithms into routine clinical cytometry diagnostic practice requires a thorough understanding of regulatory requirements and challenges throughout the cytometry software product lifecycle. To provide cytometry software developers, computational scientists, researchers, industry professionals, and diagnostic physicians/pathologists with an introduction to European Union (EU) and United States (US) regulatory frameworks. Informed by community feedback and needs assessment established during two international cytometry workshops, this article provides an overview of regulatory landscapes as they pertain to the application of AI, AI-enabled medical devices, and Software as a Medical Device in diagnostic flow cytometry...
February 23, 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38345199/enhancing-hla-b27-antigen-detection-leveraging-machine-learning-algorithms-for-flow-cytometric-analysis
#7
JOURNAL ARTICLE
Sándor Baráth, Parvind Singh, Zsuzsanna Hevessy, Anikó Ujfalusi, Zoltán Mezei, Mária Balogh, Marianna Száraz Széles, János Kappelmayer
As the association of human leukocyte antigen B27 (HLA-B27) with spondylarthropathies is widely known, HLA-B27 antigen expression is frequently identified using flow cytometric or other techniques. Because of the possibility of cross-reaction with off target antigens, such as HLA-B7, each flow cytometric technique applies a "gray zone" reserved for equivocal findings. Our aim was to use machine learning (ML) methods to classify such equivocal data as positive or negative. Equivocal samples (n = 99) were selected from samples submitted to our institution for clinical evaluation by HLA-B27 antigen testing...
February 12, 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38345160/flow-cytometry-of-dnmt1-as-a-biomarker-of-hypomethylating-therapies
#8
JOURNAL ARTICLE
Philip G Woost, Basem M William, Brenda W Cooper, Masumi Ueda Oshima, Folashade Otegbeye, Marcos J De Lima, David Wald, Reda Z Mahfouz, Yogen Saunthararajah, Tammy Stefan, James W Jacobberger
The 5-azacytidine (AZA) and decitabine (DEC) are noncytotoxic, differentiation-inducing therapies approved for treatment of myelodysplastic syndrome, acute myeloid leukemias (AML), and under evaluation as maintenance therapy for AML postallogeneic hematopoietic stem cell transplant and to treat hemoglobinapathies. Malignant cell cytoreduction is thought to occur by S-phase specific depletion of the key epigenetic regulator, DNA methyltransferase 1 (DNMT1) that, in the case of cancers, thereby releases terminal-differentiation programs...
February 12, 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38450979/analysis-of-cerebrospinal-fluid-for-the-diagnosis-of-cns-lymphoma-comparison-of-the-escca-iscca-protocol-and-real-world-data-of-the-cythem-loc-french-network
#9
LETTER
Agathe Debliquis, Guido Ahle, Caroline Houillier, Carole Soussain, Khê Hoang-Xuan, Magali Le Garff-Tavernier
No abstract text is available yet for this article.
March 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38297808/role-of-flow-cytometric-immunophenotyping-in-the-diagnosis-of-breast-implant-associated-anaplastic-large-cell-lymphoma-a-6-year-single-institution-experience
#10
REVIEW
Alexander Chan, Romany Auclair, Qi Gao, Paola Ghione, Steven Horwitz, Ahmet Dogan, Mikhail Roshal, Oscar Lin
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon mature T-cell neoplasm occurring in patients with textured breast implants, typically after 7-10 years of exposure. Although cytopathologic or histopathologic assessment is considered the gold standard diagnostic method for BIA-ALCL, flow cytometry (FC)-based immunophenotyping is recommended as an adjunct test. However, the diagnostic efficacy of FC is not well reported. We reviewed 290 FC tests from breast implant pericapsular fluid and capsule tissue from 182 patients, including 16 patients with BIA-ALCL over a 6-year period, calculating diagnostic rates and test efficacy...
March 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38247200/maturational-dyssynchrony-in-benign-b-cell-precursors-following-lymphocyte-depleting-chemotherapy-a-potential-pitfall-for-b-lymphoblastic-leukemia-minimal-measurable-residual-disease-mrd-flow-cytometry-analysis
#11
LETTER
Alexander Placek, Brian Lockhart, Karin P Miller, Gerald B Wertheim, Shannon L Maude, Brent L Wood, Alexandra E Kovach
No abstract text is available yet for this article.
March 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38010113/an-alternative-processing-approach-to-increase-cd138-intensity-in-flow-cytometric-analysis-of-plasma-cells
#12
JOURNAL ARTICLE
Deepak Kumar, F N U Kiran, Amanda Wheeler, Rory Dellamano, Richard D Hammer
BACKGROUND: Surface median immunofluorescence intensity (MFI) of plasma cells antigens, particularly CD138, by flow cytometry underestimates plasma cell populations when compared with that estimated by morphological assessment on Wright's-stained slides. CD138 MFI using traditional sample preparation methods for flow cytometric analysis is often dim and difficult to interpret due to multiple factors. This becomes critical when diagnosing and accurately classifying plasma cell dyscrasias...
March 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38243626/deciphering-stage-0-hematogones-by-flow-cytometry-in-follow-up-bone-marrow-samples-of-pediatric-b-acute-lymphoblastic-leukemia-cases-a-potential-mimicker-of-residual-disease-after-anti-cd19-therapy
#13
JOURNAL ARTICLE
Thulasi Raman Ramalingam, Lakshman Vaidhyanathan, Anurekha Muthu, Venkateswaran Vellaichamy Swaminathan, Ramya Uppuluri, Revathi Raj
CD19 is frequently targeted for immunotherapy in B cell malignancies, which may result in loss of CD19 expression in leukemic cells as an escape mechanism. Stage 0 hematogones (Hgs) are normal CD19-negative very early B cell precursors that can be potentially mistaken for CD19 negative residual leukemic cells by flow cytometry (FCM) in B cell acute lymphoblastic leukemia (BCP-ALL) cases treated with anti CD19 therapy. Our main objective was to characterize and study the incidence of stage 0 hematogones in follow-up bone marrow samples of pediatric BCP-ALL cases...
January 19, 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38189588/cd34-and-cd117-negative-pure-erythroid-leukemia-and-phenotypic-differences-with-acute-megakaryoblastic-leukemia
#14
LETTER
Alejandra Altube, Daniela Chelin, Mariela Gomez, Cecilia Malusardi, Dolores Sciaccaluga, Cecilia Cabral, Mariangeles Auat
No abstract text is available yet for this article.
January 8, 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38389395/issue-highlights-february-2024
#15
JOURNAL ARTICLE
Virginia Litwin
No abstract text is available yet for this article.
January 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38273649/ror1-expression-in-mature-b-lymphoid-neoplasms-by-flow-cytometry
#16
JOURNAL ARTICLE
Flávia Arandas de Sousa, Nádila Magalhães Millan, Rodolfo Patussi Correia, Andressa da Costa Vaz, Daniela Schimidell, Priscila Carmona Miyamoto, Marilia Sandoval Passaro, Bruna Garcia Nogueira, Elizabeth Xisto Souto, Nydia Strachman Bacal, Laiz Camerão Bento
Immunophenotyping by flow cytometry is an integral part of the diagnosis and classification of leukemias/lymphomas. The expression of ROR1 associated with chronic B lymphocytic leukemia (CLL) is well described in the literature, both in its diagnosis and in the follow-up of minimal residual disease (MRD) research, however, there are few studies regarding the expression pattern of ROR1 in other subtypes of mature B lymphoid neoplasms. With the aim of evaluating the expression of ROR1 and associating it with the expression of other important markers for the differentiation of mature B lymphoid neoplasms (MBLN), 767 samples of cases that entered our laboratory for immunophenotyping with clinical suspicion of MBLN were studied...
January 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38217297/standardization-of-flow-cytometric-detection-of-antigen-expression
#17
JOURNAL ARTICLE
Linhua Tian, Aaron R Nelson, Tyler Lowe, Linda Weaver, Constance Yuan, Hao-Wei Wang, Paul DeRose, Maryalice Stetler-Stevenson, Lili Wang
Since response to antigen-based immunotherapy relies upon the level of tumor antigen expression we developed an antigen quantification assay using ABC values. Antigen quantification as a clinical assay requires methods for quality control and for interlaboratory and inter-cytometer platform standardization. A single lot of Cytotrol™ Lyophilized Control Cells (Beckman Coulter) used for all studies. The variability in antigen quantification across 4 different instrument platforms in 2 separate laboratories was evaluated...
January 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38100186/editorial-on-ivd-cellular-assay-validation
#18
EDITORIAL
Bruce H Davis
No abstract text is available yet for this article.
December 15, 2023: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38037221/immunophenotypic-portrait-of-leukemia-associated-phenotype-markers-in-b-acute-lymphoblastic-leukemia
#19
JOURNAL ARTICLE
Emilia Boris, Alexandre Theron, Valentin Montagnon, Nicolas Rouquier, Marion Almeras, Jérôme Moreaux, Caroline Bret
BACKGROUND: Multiparametric flow cytometry (MFC) is an essential diagnostic tool in B acute lymphoblastic leukemia (B ALL) to determine the B-lineage affiliation of the blast population and to define their complete immunophenotypic profile. Most MFC strategies used in routine laboratories include leukemia-associated phenotype (LAP) markers, whose expression profiles can be difficult to interpret. The aim of our study was to reach a better understanding of 7 LAP markers' landscape in B ALL: CD9, CD21, CD66c, CD58, CD81, CD123, and NG2...
November 30, 2023: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38017706/cd5-negative-chronic-lymphocytic-leukemia-does-this-entity-really-exist
#20
JOURNAL ARTICLE
Daniel Mazza Matos
No abstract text is available yet for this article.
November 28, 2023: Cytometry. Part B, Clinical Cytometry
journal
journal
40908
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.